Literature DB >> 9832969

CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours.

G Griebel1, G Perrault, D J Sanger.   

Abstract

The present experiments compared the behavioural effects of one cholecystokininA (CCKA; lorglumide) and two CCKB (PD 135,158 and LY 288513) receptor antagonists in classical animal models of anxiety, including conflict tests (punished lever pressing and Vogel drinking tests in rats) and exploratory models (elevated plus-maze test in rats and light/dark choice test in mice), and a recently developed mouse defence test battery (MDTB) which has been validated for the screening of both anti-panic and classical anxiolytic (i.e. benzodiazepines) drugs. Diazepam was used as a positive control. Results showed that all three CCK receptor antagonists were inactive in both conflict tests. Furthermore, despite the incorporation of more ethologically-derived measures (i.e. risk assessment activities or directed exploration, or both) no effects were observed in the elevated plus-maze and in the light/dark tests. These profiles contrast with that of diazepam which displayed clear anxiolytic-like effects in these models. In the MDTB, the CCK receptor antagonists failed to modify parameters (i.e. risk assessment, defensive threat/attack and escape attempts), which have been shown to be particularly sensitive to drugs effective in the treatment of generalized anxiety. By contrast, the CCKB receptor antagnoists PD 135,158 (0.001-0.01, 1 mg/kg, i.p.) and LY 288513 (1 and 3 mg/kg, i.p.) significantly decreased avoidance distance when the rat was first placed in the test apparatus, an effect which is consistent with an anti-panic-like action. Overall, these findings support the idea that classical animal models of anxiety may not be suitable for evaluation of the behavioural effects of CCK receptor antagonists, whereas tests which may model certain aspects of human panic such as the MDTB appear to be more reliable tools when screening such compounds.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9832969     DOI: 10.1097/00008877-199711000-00013

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  7 in total

1.  The circadian gene Nr1d1 in the mouse nucleus accumbens modulates sociability and anxiety-related behaviour.

Authors:  Changjiu Zhao; Stephen C Gammie
Journal:  Eur J Neurosci       Date:  2018-08-07       Impact factor: 3.386

2.  Elevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse.

Authors:  Qian Chen; Akira Nakajima; Corbin Meacham; Ya-Ping Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-28       Impact factor: 11.205

3.  Sex differences in specific aspects of two animal tests of anxiety-like behavior.

Authors:  Thatiane De Oliveira Sergio; Leah Wetherill; Claudina Kwok; Farrah Khoyloo; Frederic W Hopf
Journal:  Psychopharmacology (Berl)       Date:  2021-06-13       Impact factor: 4.530

4.  Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention.

Authors:  Mallory E Bowers; Kerry J Ressler
Journal:  Neuropsychopharmacology       Date:  2014-09-01       Impact factor: 7.853

Review 5.  Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.

Authors:  Susan Rotzinger; Franco J Vaccarino
Journal:  J Psychiatry Neurosci       Date:  2003-05       Impact factor: 6.186

6.  Blockade of the cholecystokinin CCK-2 receptor prevents the normalization of anxiety levels in the rat.

Authors:  Santiago J Ballaz; Michel Bourin; Huda Akil; Stanley J Watson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-09-14       Impact factor: 5.067

7.  Anxiety in mice: a principal component analysis study.

Authors:  Yan Clément; Chantal Joubert; Caroline Kopp; Eve M Lepicard; Patrice Venault; René Misslin; Martine Cadot; Georges Chapouthier
Journal:  Neural Plast       Date:  2007-03-21       Impact factor: 3.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.